Illustration: Lazaro Gamio/Axios
Pharma is increasingly shelling out for platforms that could put biologic medicines — typically administered via infusion or injection — into pill form.
The big picture: Demand for oral GLP-1s and recent FDA approvals are fueling licensing deals.
